Home › Companies › Nurix Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 15, 2026: 5 items on Nurix Therapeutics, Inc.’s Form 8-K, filed May 15, 2026: 3 elected · 2 approved.
Significant dissent: 2 directors (25.8%, 20.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 4.5%, as of September 30, 2026)
Explore Nurix Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Nurix Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Arthur T. Sands, M.D., Ph.D. | 63,592,948 | -- | -- | 16,334,570 | 3,819,495 | 80% | Elected | — |
| Elect Director: Roger Dansey, M.D. | 79,607,489 | -- | -- | 320,029 | 3,819,495 | 99.6% | Elected | — |
| Elect Director: Paul M. Silva | 59,298,612 | -- | -- | 20,628,906 | 3,819,495 | 74% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 83,555,977 | 166,391 | 24,645 | -- | -- | 99.8% | Approved | — |
| 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers | 72,458,920 | 6,895,394 | 573,204 | -- | 3,819,495 | 91% | Approved | — |
Source: Nurix Therapeutics, Inc., Form 8-K, filed with the SEC on May 15, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
215 asset managers disclosed a vote on at least one Nurix Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.
Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Arthur T. Sands, M.D., Ph.D.”): 63,592,948 for, 16,334,570 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 23,121,907 for, 4,366,423 withheld, 141,473 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,167,834 | 0 | 0 | 3,564,112 | Mixed |
| Vanguard | 5,404,439 | 0 | 7,800 | 0 | For |
| BlackRock | 4,833,259 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,265,179 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,632,038 | 0 | 0 | 0 | For |
| State Street | 1,528,323 | 0 | 0 | 3,868 | For |
| MUTUAL FUND SERIES TRUST | 1,297,893 | 0 | 0 | 25,571 | For |
| Charles Schwab | 922,609 | 0 | 0 | 0 | For |
| Capital Group | 893,327 | 0 | 0 | 0 | For |
| TIAA | 744,345 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 258,949 | Withhold |
| Equitable | 187,038 | 0 | 0 | 63,470 | Mixed |
| Goldman Sachs | 211,153 | 0 | 0 | 0 | For |
| Invesco | 170,368 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 164,620 | 0 | 0 | 0 | For |
| Brighthouse | 65,163 | 0 | 0 | 32,631 | Mixed |
| CARILLON SERIES TRUST | 0 | 0 | 88,158 | 0 | Abstain |
| Nationwide | 50,533 | 0 | 0 | 31,966 | Mixed |
| American Century | 0 | 0 | 0 | 77,991 | Withhold |
| Northern Trust | 70,735 | 0 | 0 | 0 | For |
| Lincoln Financial | 66,600 | 0 | 0 | 1,279 | For |
| Global X | 67,374 | 0 | 0 | 0 | For |
| John Hancock | 30,577 | 0 | 29,298 | 0 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 58,276 | Withhold |
| Columbia Threadneedle | 56,135 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Paul M. Silva
Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Paul M. Silva”): 59,298,612 for, 20,628,906 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 21,391,262 for, 6,097,061 withheld, 141,479 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,167,834 | 0 | 0 | 3,564,112 | Mixed |
| Vanguard | 5,400,751 | 0 | 7,806 | 3,682 | For |
| BlackRock | 4,833,259 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,265,179 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,632,038 | 0 | 0 | 0 | For |
| State Street | 1,030 | 0 | 0 | 1,531,161 | Withhold |
| MUTUAL FUND SERIES TRUST | 1,297,893 | 0 | 0 | 25,571 | For |
| Charles Schwab | 922,609 | 0 | 0 | 0 | For |
| Capital Group | 893,327 | 0 | 0 | 0 | For |
| TIAA | 744,345 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 258,949 | Withhold |
| Equitable | 187,038 | 0 | 0 | 63,470 | Mixed |
| Goldman Sachs | 211,153 | 0 | 0 | 0 | For |
| Invesco | 170,368 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 164,620 | 0 | 0 | 0 | For |
| Brighthouse | 65,163 | 0 | 0 | 32,631 | Mixed |
| CARILLON SERIES TRUST | 0 | 0 | 88,158 | 0 | Abstain |
| Nationwide | 50,533 | 0 | 0 | 31,966 | Mixed |
| American Century | 0 | 0 | 0 | 77,991 | Withhold |
| Northern Trust | 0 | 0 | 0 | 70,735 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 67,879 | Withhold |
| Global X | 46,204 | 0 | 0 | 21,170 | Mixed |
| John Hancock | 30,577 | 0 | 29,298 | 0 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 58,276 | Withhold |
| Columbia Threadneedle | 56,135 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Roger Dansey, M.D.
Nurix Therapeutics, Inc.’s own tally for this item (“Elect Director: Roger Dansey, M.D.”): 79,607,489 for, 320,029 withheld, per its Form 8-K filed May 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 27,629,803 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,731,946 | 0 | 0 | 0 | For |
| Vanguard | 5,412,239 | 0 | 0 | 0 | For |
| BlackRock | 4,833,259 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,265,179 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,632,038 | 0 | 0 | 0 | For |
| State Street | 1,532,191 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,323,464 | 0 | 0 | 0 | For |
| Charles Schwab | 922,609 | 0 | 0 | 0 | For |
| Capital Group | 893,327 | 0 | 0 | 0 | For |
| TIAA | 744,345 | 0 | 0 | 0 | For |
| Dimensional | 258,949 | 0 | 0 | 0 | For |
| Equitable | 250,508 | 0 | 0 | 0 | For |
| Goldman Sachs | 211,153 | 0 | 0 | 0 | For |
| Invesco | 170,368 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 164,620 | 0 | 0 | 0 | For |
| Brighthouse | 97,794 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 88,158 | 0 | 0 | 0 | For |
| Nationwide | 82,499 | 0 | 0 | 0 | For |
| American Century | 77,991 | 0 | 0 | 0 | For |
| Northern Trust | 70,735 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,879 | 0 | 0 | 0 | For |
| Global X | 67,374 | 0 | 0 | 0 | For |
| John Hancock | 59,875 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 58,276 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 56,135 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
91% Approved · of votes cast
Prior year: 81.5% for (May 19, 2025 meeting) ▲ 9.9 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.
Nurix Therapeutics, Inc.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 72,458,920 for, 6,895,394 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,167,834 | 3,564,112 | 0 | 0 | Mixed |
| Vanguard | 5,412,225 | 12 | 1 | 0 | For |
| BlackRock | 4,833,259 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,265,179 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,632,038 | 0 | 0 | 0 | For |
| State Street | 1,532,131 | 60 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,323,464 | 0 | 0 | 0 | For |
| Charles Schwab | 922,609 | 0 | 0 | 0 | For |
| Capital Group | 0 | 893,327 | 0 | 0 | Against |
| TIAA | 744,345 | 0 | 0 | 0 | For |
| Dimensional | 258,949 | 0 | 0 | 0 | For |
| Equitable | 250,508 | 0 | 0 | 0 | For |
| Goldman Sachs | 211,153 | 0 | 0 | 0 | For |
| Invesco | 0 | 170,368 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 164,620 | 0 | 0 | 0 | For |
| Brighthouse | 97,794 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 88,158 | 0 | 0 | 0 | For |
| Nationwide | 82,499 | 0 | 0 | 0 | For |
| American Century | 0 | 77,991 | 0 | 0 | Against |
| Northern Trust | 70,735 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,879 | 0 | 0 | 0 | For |
| Global X | 67,374 | 0 | 0 | 0 | For |
| John Hancock | 59,875 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 58,276 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 56,135 | 0 | 0 | 0 | For |
Fund voting reports, all 56 managers: 22,923,931 for, 4,705,870 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Redmile Group, LLC | 7,902,808 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 5,198,303 | 0 | 0 | 0 | For |
| Fidelity | 0 | 4,860,200 | 0 | 0 | Against |
| BAKER BROS. ADVISORS LP | 4,597,916 | 0 | 0 | 0 | For |
| State Street | 3,448,820 | 18,640 | 0 | 0 | For |
| BlackRock | 3,440,394 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,205,718 | 0 | 0 | 0 | For |
| GENERAL ATLANTIC, L.P. | 0 | 0 | 3,032,185 | 0 | Abstain |
| Vestal Point Capital, LP | 3,023,716 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,480,162 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 2,470,194 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 2,447,623 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 2,307,270 | 0 | 0 | 0 | For |
| Commodore Capital LP | 1,662,871 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 1,412,367 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 1,186,447 | 0 | 0 | 0 | For |
| Charles Schwab | 922,942 | 0 | 0 | 0 | For |
| Capital Group | 0 | 893,327 | 0 | 0 | Against |
| Nuveen | 780,321 | 0 | 0 | 0 | For |
| Vanguard | 721,073 | 0 | 0 | 0 | For |
| Northern Trust | 659,792 | 7,040 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 628,444 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 0 | 534,259 | 0 | Abstain |
| BRAIDWELL LP | 524,296 | 0 | 0 | 0 | For |
| Handelsbanken Fonder AB | 492,298 | 0 | 0 | 0 | For |
Institutional-manager reports, all 174 managers: 56,682,464 for, 6,454,081 against, 473,485 withheld, 3,567,019 abstained, 352 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Prior year: 99.9% for (May 19, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.
Nurix Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 83,555,977 for, 166,391 against — passed, per its Form 8-K filed May 15, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 27,629,743 for, 60 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,731,946 | 0 | 0 | 0 | For |
| Vanguard | 5,412,239 | 0 | 0 | 0 | For |
| BlackRock | 4,833,259 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,265,179 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,632,038 | 0 | 0 | 0 | For |
| State Street | 1,532,131 | 60 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,323,464 | 0 | 0 | 0 | For |
| Charles Schwab | 922,609 | 0 | 0 | 0 | For |
| Capital Group | 893,327 | 0 | 0 | 0 | For |
| TIAA | 744,345 | 0 | 0 | 0 | For |
| Dimensional | 258,949 | 0 | 0 | 0 | For |
| Equitable | 250,508 | 0 | 0 | 0 | For |
| Goldman Sachs | 211,153 | 0 | 0 | 0 | For |
| Invesco | 170,368 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 164,620 | 0 | 0 | 0 | For |
| Brighthouse | 97,794 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 88,158 | 0 | 0 | 0 | For |
| Nationwide | 82,499 | 0 | 0 | 0 | For |
| American Century | 77,991 | 0 | 0 | 0 | For |
| Northern Trust | 70,735 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,879 | 0 | 0 | 0 | For |
| Global X | 67,374 | 0 | 0 | 0 | For |
| John Hancock | 59,875 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 58,276 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 56,135 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,405,813 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.54% |
| 2 | Vanguard | 5.23% |
| 3 | BlackRock | 4.67% |
| 4 | T. Rowe Price | 2.19% |
| 5 | ARK ETF Trust | 1.58% |
| 6 | State Street | 1.48% |
| 7 | MUTUAL FUND SERIES TRUST | 1.28% |
| 8 | Charles Schwab | 0.89% |
| 9 | Capital Group | 0.86% |
| 10 | TIAA | 0.72% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Redmile Group, LLC | 7.64% |
| 2 | Deep Track Capital, LP | 5.03% |
| 3 | Fidelity | 4.70% |
| 4 | BAKER BROS. ADVISORS LP | 4.45% |
| 5 | State Street | 3.35% |
| 6 | BlackRock | 3.33% |
| 7 | T. Rowe Price | 3.10% |
| 8 | GENERAL ATLANTIC, L.P. | 2.93% |
| 9 | Vestal Point Capital, LP | 2.92% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.40% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 8,925,642 | 8.63% | Form 13F, quarter ended March 31, 2026 |
| Redmile Group, LLC | 8,782,256 | 8.49% | Schedule 13G, filed August 14, 2026 |
| Vestal Point Capital, LP | 8,050,000 | 7.78% | Schedule 13G, filed August 14, 2026 |
| Deep Track Capital, LP | 7,736,455 | 7.48% | Schedule 13G, filed August 14, 2026 |
| Baker Bros. Advisors LP | 7,527,996 | 7.28% | Schedule 13G, filed February 17, 2026 |
| Rubric Capital Management LP | 7,227,778 | 6.99% | Schedule 13G, filed August 14, 2026 |
| Vanguard Group | 5,949,512 | 5.75% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 5,541,271 | 5.36% | Form 13F, quarter ended March 31, 2026 |
| State Street | 5,141,195 | 4.97% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 4,881,069 | 4.72% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 103,405,813 shares outstanding, as reported by Nurix Therapeutics, Inc. on its Form 10-Q dated April 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Nurix Therapeutics, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 215 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,232 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — Nurix Therapeutics, Inc.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nurix Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nurix Therapeutics, Inc.’s 10-Q dated April 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Nurix Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Nurix Therapeutics (NRIX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nurix-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.